CLDX Q1 2025 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$695,000+345.5% YoY

Gross Profit

$695,000100.0% margin

Operating Income

-$63M-9027.2% margin

Net Income

-$54M-7740.4% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-40.9%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$739M

Total Liabilities

$36M

Stockholders' Equity

$703M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$695,000	$156,000	+345.5%
Gross Profit	$695,000	-$619,000	+212.3%
Operating Income	-$63M	-$41M	-54.5%
Net Income	-$54M	-$33M	-64.0%

Revenue Segments

Grant

$645,00093%

Service

$50,0007%